HC Wainwright Weighs in on Alkermes plc’s Q1 2025 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Alkermes in a research note issued on Thursday, May 2nd. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of $0.43 for the quarter. HC Wainwright has a “Neutral” rating and a $35.00 price target on the stock. The consensus estimate for Alkermes’ current full-year earnings is $2.39 per share. HC Wainwright also issued estimates for Alkermes’ Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.54 EPS and Q4 2025 earnings at $0.52 EPS.

A number of other equities analysts have also weighed in on the stock. Robert W. Baird initiated coverage on shares of Alkermes in a research report on Tuesday, March 19th. They set an “outperform” rating and a $37.00 price target on the stock. TheStreet upgraded Alkermes from a “c+” rating to a “b” rating in a research report on Thursday, February 15th. Jefferies Financial Group lifted their price objective on Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Piper Sandler restated an “overweight” rating and issued a $39.00 target price on shares of Alkermes in a report on Monday, April 1st. Finally, UBS Group lowered Alkermes from a “neutral” rating to a “sell” rating and set a $25.00 price target on the stock. in a report on Tuesday, February 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Hold” and a consensus price target of $35.38.

Alkermes Trading Up 2.0 %

Shares of ALKS opened at $24.59 on Monday. Alkermes has a 52-week low of $22.01 and a 52-week high of $33.71. The stock has a market cap of $4.16 billion, a PE ratio of 9.72, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm’s fifty day moving average is $26.50 and its two-hundred day moving average is $26.70. The company has a quick ratio of 2.77, a current ratio of 3.20 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.15). Alkermes had a net margin of 25.17% and a return on equity of 20.31%. The firm had revenue of $350.37 million during the quarter, compared to analysts’ expectations of $360.26 million. During the same quarter last year, the business earned ($0.10) EPS. The business’s revenue was up 21.8% compared to the same quarter last year.

Institutional Trading of Alkermes

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC increased its stake in Alkermes by 6.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 7,830 shares of the company’s stock worth $219,000 after buying an additional 452 shares during the period. Victory Capital Management Inc. raised its stake in shares of Alkermes by 0.6% in the third quarter. Victory Capital Management Inc. now owns 76,043 shares of the company’s stock valued at $2,130,000 after acquiring an additional 481 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of Alkermes by 0.4% in the third quarter. Alps Advisors Inc. now owns 122,916 shares of the company’s stock valued at $3,443,000 after acquiring an additional 529 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Alkermes by 1.0% in the fourth quarter. Fisher Asset Management LLC now owns 59,942 shares of the company’s stock valued at $1,663,000 after purchasing an additional 572 shares during the period. Finally, New York State Common Retirement Fund grew its stake in Alkermes by 0.4% during the 3rd quarter. New York State Common Retirement Fund now owns 143,223 shares of the company’s stock worth $4,012,000 after purchasing an additional 605 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Christian Todd Nichols sold 10,417 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $28.10, for a total value of $292,717.70. Following the sale, the senior vice president now directly owns 65,911 shares of the company’s stock, valued at approximately $1,852,099.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.76% of the stock is currently owned by insiders.

Alkermes announced that its board has initiated a share repurchase plan on Thursday, February 15th that authorizes the company to repurchase $400.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 8.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.